AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical companies testing the pairing of antibody drug conjugates with PD-1/VEGF bispecific antibodies, a drug combination that could offer advantages in cancer treatment.

The post AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug appeared first on MedCity News.